Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLS | O94925 | 1/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | ACKR3 | P25106 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.41 |
| ▸ | KIF18A | Q8NI77 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.40 |
| ▸ | PTGES | O14684 | 1/20 | 0.40 |
| ▸ | BACE1 | P56817 | 1/20 | 0.39 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18083762 | 0.87 | RXFP1 (0.45) | RXFP1ACKR3TP53PTPN11KIF18A | |
| SCHEMBL18083782 | 0.85 | RXFP1 (0.51) | RXFP1ACKR3MAPTPTPN11PTGES | |
| SCHEMBL18083765 | 0.82 | CHRM3 (0.53) | GLSRXFP1ACKR3TP53CHRM3 | |
| SCHEMBL18083681 | 0.82 | ACKR3 (0.54) | RXFP1ACKR3MAPTTP53PTPN11 | |
| SCHEMBL28864301 | 0.75 | ALDH1A1 (0.61) | MAPTTP53 | |
| SCHEMBL18083727 | 0.75 | LMNA (0.50) | RXFP1TP53PTGES | |
| SCHEMBL25933 | 0.74 | POLB (0.58) | — | |
| SCHEMBL24765850 | 0.73 | VEGFA (0.48) | MAPTTP53CHRM2CHRM4CHRM1 | |
| SCHEMBL18291473 | 0.73 | CHRM2 (0.46) | CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL29132142 | 0.73 | FNTA (0.49) | ACKR3CHRM2CHRM4CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3271348-B1 | NEW FYN KINASE INHIBITORS | Rottapharm Biotech Srl (IT) | 2019-01-30 | — | — | EP | disclosed |
| US-20180111919-A1 | NEW FYN KINASE INHIBITORS | ROTTAPHARM BIOTECH S.R.L. (IT) | 2018-04-26 | — | — | US | disclosed |
| WO-2016146220-A1 | NEW FYN KINASE INHIBITORS | ROTTAPHARM BIOTECH S.R.L. (IT) | 2016-09-22 | — | — | WO | disclosed |
| EP-3070084-A1 | NEW FYN KINASE INHIBITORS | Rottapharm Biotech S.r.l. (IT) | 2016-09-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180111919-A1 | NEW FYN KINASE INHIBITORS | FYN, LCK, LYN | GLS 2524/4885RXFP1 1608/4885ACKR3 533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.